After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...

Intellia earlier this year reported a similar grade 4 liver enzyme elevation associated with the gene therapy nexiguran ...

Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...

The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

Twisted graphene precisely aligned with gold nanodisks and coupled with CRISPR achieves attomolar detection of cancer biomarkers, revealing a new path for low light molecular diagnostics. (Nanowerk ...

A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...

In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...

Nex-z is one of two late-stage projects on the go at Intellia, a specialist in CRISPR gene-editing co-founded by Nobel Prize ...

A newly discovered nuclear role for HSL reveals how imbalances in its location within fat cells may contribute to both ...